Dr. Carl Jack Fichtenbaum, MD

Dr. Fichtenbaum practices at UC Medical Center in Cincinnati, Ohio.

Dr. Fichtenbaum's NPI, 1073578951, was assigned on April 20, 2006. Dr. Fichtenbaum graduated from University of Missouri, Columbia School of Medicine in 1985. Dr. Fichtenbaum holds Ohio license 35-076757.

Dr. Fichtenbaum's primary practice is UC Medical Center, at 3188 Bellevue Ave, Cincinnati, OH 45219 in Hamilton County. The practice phone is (513) 584-1000.

Dr. Fichtenbaum's primary practice is UC Medical Center in Cincinnati, Ohio. Dr. Fichtenbaum is also affiliated with University of Cincinnati Medical Center. The medical group on file is University of Cincinnati Physicians. Dmand AI also links Dr. Fichtenbaum to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fichtenbaum practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Fichtenbaum's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Fichtenbaum is licensed in Ohio.

CMS data shows 155 Medicare services from Dr. Fichtenbaum across 5 procedure codes in 2024, for 63 Medicare patients. Medicare paid $6,049 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 63 Medicare patients who saw Dr. Fichtenbaum in 2024. The largest group is 65 to 74, with 32 patients. 63% of them have high blood pressure, and 62% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fichtenbaum's median patient age at 59, with 31% women.

In 2024, Dr. Fichtenbaum wrote 3,442 Medicare Part D claims for 109 patients. 59% of them were for generic drugs. CMS names the drug for 2,946 of them, across 89 drugs with 11 or more claims each, at $3,737,999 in total drug cost. In 2023, CMS named 2,745 claims across 80 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Fichtenbaum for performance year 2024, reported as part of a group. Dr. Fichtenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 89 papers to Dr. Fichtenbaum, published from 2000 to 2025. 2025 was the busiest year, with 8. The most frequent topics are HIV Infections, Cardiovascular Diseases and Anti-HIV Agents. Dr. Fichtenbaum has published most often in Clin Infect Dis. Dr. Fichtenbaum's most frequent co-authors are Steven Kyle Grinspoon, MD, Markella V. Zanni, MD and Judith Ann Aberg, MD.

Dmand AI links Dr. Fichtenbaum to 11 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include HIV Infections, Lentivirus Infections and COVID-19. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections sponsors the most, 5. Open Payments lists research payments to Dr. Fichtenbaum that name 1 trial.

CMS Open Payments shows 57 general payments to Dr. Fichtenbaum from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Janssen Pharmaceuticals, Inc paid the most, $4,387. It also lists 16 research payments totaling $15,261 from 2021 to 2025, naming 1 clinical trial.

Dr. Fichtenbaum graduated from University of Missouri, Columbia School of Medicine in 1985.